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Introduction
In response to infection, tissue damage, or chronic inflamma-
tion, cells produce proinflammatory cytokines such as TNF, 
interleukin-1β (IL-1β), andIFN-γ that have pleiotropic effects 
on blood vessels surrounding the inflammatory focus. These 
cytokines trigger a transcriptional program in the endothe-
lium to express proteins necessary for a long-term inflamma-
tory response, including those involved in altering endothelial 
barrier function. The pathological expression of some of these 
proteins contributes to the development of inflammatory 
and thrombotic diseases (Libby, 2002; Compston and Coles, 
2008; Khan et al., 2010).
The family of Rho GTPases contains more than 20 mem-
bers that regulate multiple cellular functions. The founder 
member of this family, RhoA, is closely related to RhoB and 
RhoC. These three GTPases are often considered as a RhoA 
subfamily whose members share 88% amino acid identity and 
have the potential to regulate common effectors, such as Rho 
kinases (ROCKs; Ridley, 2013). However, RhoA, RhoB, and 
RhoC have remarkably different effects on cancer cell migra-
tion, which indicate that they also regulate different signaling 
pathways (Ridley, 2013). The three GTPases in their active state 
are associated with the plasma membrane, but only RhoB is 
also localized to the endosomal compartment (Ridley, 2013). 
In the endothelium, the signaling pathways controlled by the 
RhoA subfamily are essential for maintaining the barrier integ-
rity, mainly by regulating ROCKs, which drive actomyosin-me-
diated contractile force generation and modulate cell–cell 
junctions (Wojciak-Stothard and Ridley, 2002; van Nieuw Am-
erongen et al., 2007; Vandenbroucke et al., 2008). Despite the 
importance of this signaling pathway, the relative contribution 
of each RhoA subfamily member to endothelial barrier function 
has not been yet characterized. On the other hand, the plasma 
membrane localization of another Rho GTPase, Rac1, is central 
to endothelial cell–cell junction remodeling and stabilization 
(Garcia et al., 2001; Cain et al., 2010; Marcos-Ramiro et al., 
2014). Interestingly, Rac1 endosomal internalization and re-
cycling are necessary for the polarized targeting and function 
of this GTPase to plasma membrane domains, such as circular 
Endothelial barrier dysfunction underlies chronic inflammatory diseases. In searching for new proteins essential to the 
human endothelial inflammatory response, we have found that the endosomal GTPase RhoB is up-regulated in response 
to inflammatory cytokines and expressed in the endothelium of some chronically inflamed tissues. We show that al-
though RhoB and the related RhoA and RhoC play additive and redundant roles in various aspects of endothelial barrier 
function, RhoB specifically inhibits barrier restoration after acute cell contraction by preventing plasma membrane ex-
tension. During barrier restoration, RhoB trafficking is induced between vesicles containing RhoB nanoclusters and 
plasma membrane protrusions. The Rho GTPase Rac1 controls membrane spreading and stabilizes endothelial barriers. 
We show that RhoB colocalizes with Rac1 in endosomes and inhibits Rac1 activity and trafficking to the cell border 
during barrier recovery. Inhibition of endosomal trafficking impairs barrier reformation, whereas induction of Rac1 
translocation to the plasma membrane accelerates it. Therefore, RhoB-specific regulation of Rac1 trafficking controls 
endothelial barrier integrity during inflammation.
RhoB controls endothelial barrier recovery by 
inhibiting Rac1 trafficking to the cell border
Beatriz Marcos-Ramiro,1 Diego García-Weber,1 Susana Barroso,1 Jorge Feito,2 María C. Ortega,1 
Eva Cernuda-Morollón,3 Natalia Reglero-Real,1 Laura Fernández-Martín,1 Maria C. Durán,4 Miguel A. Alonso,1 
Isabel Correas,1 Susan Cox,5 Anne J. Ridley,5 and Jaime Millán1
1Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Cientificas, Universidad Autónoma de Madrid, 28049 Madrid, Spain
2Servicio de Anatomía Patológica, Hospital Universitario de Salamanca, 37007 Salamanca, Spain
3Neurology Department, Hospital Universitario Central de Asturias, 33011 Oviedo, Spain
4Biomedicine, Biotechnology and Public Health Department, University of Cadiz, 11519 Cadiz, Spain
5Randall Division of Cell and Molecular Biophysics, King’s College London, SE1 1UL London, England, UK
© 2016 Marcos-Ramiro et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the 
publication date (see http ://www .rupress .org /terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 
as described at http ://creativecommons .org /licenses /by -nc -sa /3 .0 /).
Correspondence to Jaime Millán: jmillan@cbm.csic.es
Abbreviations used in this paper: DN, dominant negative; FA, focal adhesion; 
HDM VEC, human dermal microvascular endothelial cell; HGF, hepatic growth 
factor; HUV EC, human umbilical vein endothelial cell; IL-1β, interleukin-1β; MLC, 
myosin light chain; ROCK, Rho kinase; STED, stimulated emission depletion; 
STO RM, stochastic optical reconstruction microscopy; TEER, transendothelial 
electric resistance.
T
H
E
J
O
U
R
N
A
L
O
F
C
E
L
L
B
IO
L
O
G
Y
o
n
 Septem
ber 27, 2016
D
ow
nloaded from
 
Published May 2, 2016
 http://jcb-dataviewer.rupress.org/jcb/browse/12554
Original image data can be found at: 
/content/suppl/2016/04/27/jcb.201504038.DC1.html 
Supplemental Material can be found at:
 http://jcb-dataviewer.rupress.org/jcb/browse/12554
 
This article has original data in the JCB Data Viewer
JCB • Volume 213 • NumBer 3 • 2016386
ruffles in motile tumor cells (Palamidessi et al., 2008). To date, 
the role of Rac1 intracellular trafficking in the maintenance of 
endothelial barrier function has not been addressed.
Vascular injury is a hallmark of physiological and patho-
logical inflammation. Prothrombotic proteases and inflamma-
tory mediators induce acute endothelial hyperpermeability that 
can cause fatal vascular dysfunction (van Nieuw Amerongen 
et al., 1998; Levi et al., 2004). Among them, thrombin is of 
particular relevance in chronic inflammation because it can 
act synergistically with inflammatory cytokines, such as TNF, 
to modulate endothelial permeability (Tiruppathi et al., 2001) 
and to activate pathways implicated in the long-term inflam-
matory response (Levi et al., 2004; Liu et al., 2004). Thrombin 
is thus determinant in various pathological scenarios, includ-
ing inflammatory bowel diseases, such as Crohn’s disease 
(Saibeni et al., 2010). In general, acute endothelial contraction 
caused by thrombin and other inflammatory factors worsens 
pathologies related to chronic inflammation (Croce and Libby, 
2007; Popović et al., 2012).
Here, in an expression screen for proteins up-regulated in 
endothelial cells during inflammation, we have found that RhoB 
protein levels are increased three- to fivefold in response to in-
flammatory cytokines. RhoB is expressed in small vessels from 
inflamed intestine or in endothelial beds with high permeability 
such as those in hepatic sinusoids. We show that RhoB, in con-
junction with RhoA and RhoC, plays redundant and additive 
roles that control various aspects of endothelial barrier function, 
including ROCK-mediated signaling. In addition to this collab-
orative role, RhoB is specifically involved in sustaining acute 
contraction upon thrombin exposure in a context of inflamma-
tion. RhoB negatively regulates Rac1 activity and Rac1 intra-
cellular trafficking during barrier recovery. This effect impairs 
the formation of plasma membrane extensions, inhibits barrier 
reformation, and makes endothelium persistently exposed to in-
flammatory cytokines less resistant to mediators that challenge 
the integrity of the endothelial monolayer.
Results
RhoB expression is increased in response 
to inflammatory cytokines and in vessels 
from human inflamed tissues
TNF reduces endothelial barrier integrity, which progressively 
increases vascular permeability to blood cells and small mole-
cules through mechanisms that are not fully understood (Brad-
ley, 2008). To identify new proteins regulating endothelial 
barrier function during the inflammatory response, we have 
combined quantitative PCR (qPCR), proteomics, and Western 
blotting to search for proteins whose expression is modulated 
by TNF. A time course of TNF or IL-1β stimulation in human 
umbilical vein endothelial cells (HUV ECs) revealed that RhoB 
protein levels increase between 4 h and 24 h poststimulation, 
reaching a maximum fivefold increase for TNF and threefold 
increase for IL-1β compared with unstimulated cells (Fig.  1, 
A and B; and Fig. S1 A). No changes were detected in RhoA 
expression, whereas RhoC expression moderately increased 
in response to TNF. Primary human dermal microvascular en-
dothelial cells (HDM VECs; Figs. 1 C and S1 B) and human 
endothelial cell lines (Fig. S1, C and D) also increased RhoB 
expression in response to TNF. The RhoB increment was mod-
erate in epithelial cell lines (Fig. S1 D). RhoB localizes in 
endosomes, the cytosol, and the plasma membrane (Sandilands 
et al., 2004). Immunofluorescence analysis of endogenous 
RhoB showed that TNF increased RhoB expression mostly in 
a vesicular, endosomal-like compartment (Fig. 1, B and C). A 
qPCR analysis of HUV EC mRNA revealed a fourfold increase 
in RhoB mRNA and no significant changes in RhoA and RhoC 
mRNA in response to TNF (Fig. 1 D). In the whole Rho fam-
ily, only the expression of Rnd1 mRNA was also significantly 
increased in response to TNF, whereas RhoH transcripts were 
not detected (Fig. S1 E). We quantified the relative expres-
sion levels of endogenous RhoA, RhoB, and RhoC proteins 
and found that they were similar in TNF-stimulated HUV ECs 
(Fig. S1 F). The increase in GTP loading in response to TNF 
was moderate, with no statistical significance for each of the 
three Rho proteins (Fig. 1, E and F). The use of a panel of in-
hibitors suggested that TNF raises the level of RhoB expression 
mainly through a NF-κB–dependent pathway (Fig. S1, G and 
H). Therefore, these results indicate that RhoB expression in-
creases upon long-term exposure to inflammatory cytokines. As 
a result, RhoA, RhoB, and RhoC are similarly expressed and 
activated in TNF-stimulated endothelial cells.
Immunohistochemical analysis showed that RhoB ex-
pression was weak in control umbilical cords (Fig.  2  A), in 
agreement with our results obtained in vitro from unstimulated 
HUV ECs. RhoB expression was detected in some blood vessels 
from colon and small intestine tissue of patients with Crohn’s 
disease (Fig. 2, B–D). Endothelial RhoB expression was local-
ized in vessels in close proximity to fissures, the most inflamed 
and damaged areas of the tissue (Fig. S2, A–F; and Table S1), 
whereas vessels in the adjacent areas appeared negative (Fig. S2, 
A, D, and G–I) as did an isotype-specific control antibody (Fig. 
S2 J). RhoB-positive vessels were expressing low levels of the 
NG2 proteoglycan, suggesting that RhoB is highly expressed in 
postcapillary venules (Fig. 2, E–G). We also found RhoB ex-
pression in blood vessels irrigating inflamed ganglia in colon 
adenopathies associated with tumors (Fig. S2, K and L). We did 
not detect expression of RhoB in the endothelium of atheroma 
plaques from the carotid and aorta on in the normal small intes-
tine (unpublished data). The liver parenchyma contains highly 
permeable vessels called sinusoids. RhoB was highly expressed 
not only in the sinusoidal endothelium from rejected human 
liver allografts and livers in advanced stages of hepatitis B virus 
infection but also in control donors (Fig. 2, H and I; and Table 
S1). Therefore, high levels of RhoB protein expression were 
detected in inflamed small blood vessels in human intestine and 
liver sinusoids, suggesting that RhoB protein levels are higher 
in endothelial beds with diminished barrier function.
A screening of endothelial barrier function 
reveals additive, redundant, and negative 
roles of the RhoA-subfamily proteins in 
unstimulated and TNF-stimulated HUV ECs
The involvement of the Rho pathway in human cell barrier 
function has most often been addressed by inhibiting the entire 
RhoA protein subfamily or their common downstream effectors 
(McKenzie and Ridley, 2007; Fernández-Martín et al., 2012). 
Hence, we aimed to determine whether up-regulated RhoB 
plays a specific role in different barrier properties of human en-
dothelial cells during inflammation (summarized in Table 1) by 
silencing the expression of each RhoA subfamily member with 
siRNA oligonucleotides (Fig. S3, A–D). Single and double Rho 
gene silencing induced expression changes in the remaining 
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Rho proteins. RhoA depletion increased the expression of 
RhoB and RhoC by 2- to 2.5-fold, whereas single knockdown 
of RhoB increased RhoA and RhoC expression by 1.5- to 
2-fold. Knockdown of RhoC moderately increased RhoA ex-
pression in TNF-stimulated and unstimulated cells, whereas re-
duced RhoB expression by 30% only in unstimulated HUV ECs. 
Double reduction of Rho proteins caused a stronger compensa-
tory increase in the expression of the remaining GTPases (Fig. 
S3, B and C). This suggests that RhoA, RhoB, and RhoC play 
additive or redundant roles in endothelial cells, which features 
mechanisms to modulate their expression and compensate for 
each other´s function. Indeed, individual depletion of RhoB and 
RhoC, but not RhoA, as well as the double Rho knockdown, 
decreased barrier function in unstimulated HUV ECs, but this 
decrease was stronger upon triple Rho depletion (Fig. S3 E). 
These results suggest that RhoA, RhoB, and RhoC play addi-
tive roles in regulating constitutive endothelial barrier function. 
Electric cell substrate impedance sensing assays, which mea-
sures transendothelial electric resistance (TEER), and transwell 
permeability assays indicated that RhoC plays a predominant 
role in maintaining the integrity of the endothelial barrier in the 
absence of inflammatory stimuli (Fig. S3, E and F). We then ex-
amined the relative contribution of each Rho protein to the reg-
ulation of F-actin. Single Rho knockdown was not sufficient to 
reduce F-actin levels. In contrast, cells expressing only RhoB or 
RhoA, as well as cells depleted of the three GTPases, reduced 
them (Fig. S3, G and H). Collectively, these results indicate that 
these three GTPases play redundant roles in the regulation of 
F-actin. It is of note that cells expressing only RhoC had higher 
levels of F-actin, suggesting that RhoC expression is sufficient 
to mediate actin polymerization.
We investigated the role of RhoB in the endothelial bar-
rier function of cells exposed to TNF. Single Rho protein de-
pletion had no effect on permeability in cells stimulated with 
TNF between 7 and 24 h (Fig. 3, A and B). The F-actin levels 
and the T cell transendothelial migration were neither affected 
by individual Rho knockdown in TNF-stimulated HUV ECs 
(Fig. S4, A–C). Discontinuous adherens junctions connect-
ing actin stress fibers from adjacent cells regulate intercellu-
lar tension and are increased in response to TNF (Millán et 
Figure 1. RhoB is up-regulated in response to TNF in primary human endothelial cells. (A) HUV ECs were starved for 12 h and stimulated at different 
times with 10 ng/ml TNF. Right graphs quantify the expression changes of RhoA, RhoB, and RhoC in response to TNF. Mean + SEM of three different ex-
periments. **, P = 0.001; *, P = 0.02 (B) HUV ECs were left unstimulated or stimulated with TNF for 7 h, then fixed and stained with an antibody to RhoB 
and with phalloidin-TRI TC to detect F-actin. TNF increased RhoB staining (enlarged areas). (C) HDM ECs were stimulated with TNF at the indicated times 
and stained for the indicated proteins. (D) HUV ECs were stimulated with TNF at different times, and RhoA, RhoB, and RhoC transcripts were analyzed by 
qPCR. Results were normalized to mRNA levels of β-actin and GAD PH. Mean + SEM from four different experiments. Statistical significance tested for the 
three graphs *, P = 0.022. (E and F) Effect of 7-h TNF stimulation on active Rho proteins detected by pull-down assays. (F) Mean + SEM of six different 
experiments. No statistical significance with the Student’s t test was found for any data comparison in the three graphs. Bars, 20 µm.
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al., 2010; Huveneers et al., 2012). The single reduction of 
each Rho protein had no apparent effect on the morphology 
of adherens junctions, whereas triple Rho knockdown turned 
them into linear junctions interspersed with big gaps (Fig. S4, 
A and B). Therefore, TEER and F-actin levels were reduced 
in TNF-stimulated cells simultaneously silenced for the three 
Rho GTPases, although this could not be attributed to a specific 
effect on TNF-mediated signaling because it was also observed 
before the TNF exposure (Fig. S3, G and H). However, the 
inhibition of ROCK, the main Rho downstream effector that 
controls actomyosin levels, did not prevent the reduction in 
TEER in TNF-stimulated cells (Fig. 3 A) as we had previously 
observed (McKenzie and Ridley, 2007; Fernández-Martín 
et al., 2012). This suggests that the RhoA GTPase subfamily 
has no significant role in long-term endothelial barrier disrup-
tion in response to TNF.
Table 1. Functional screening of the effect of RhoA, RhoB, and RhoC siRNAs on the barrier properties of human primary endothelial cells
Barrier analysis/siRNA RhoA RhoB RhoC RhoA/B/C
Unstimulated HUV ECs
Constitutive barrier function −/+ + ++ +++
F-actin levels − − − +++
TNF-stimulated HUV ECs
TNF-induced barrier dysfunction − − − ND
TNF-induced F-actin increase − − − +++
Leukocyte transendothelial migration (static) − − − −
Acute cell contraction −/+ + −/+ +++
Barrier restoration after contraction − +++ −/+ +++
ND, not determined.
Figure 2. RhoB is expressed in intestinal vessels of patients 
with Crohn’s disease and hepatic sinusoids. (A) Moderate 
immunohistochemical staining of RhoB from human umbilical 
veins. (B–D) Large intestine from a patient with Crohn’s dis-
ease showing intense endothelial RhoB staining (arrows) in 
inflamed vessels containing high levels of adhered immune 
cells. (C and D) Differential RhoB staining, which suggests 
increased RhoB expression in vessel areas with high levels 
of leukocyte adhesion and capillary hyperplasia (arrows), 
with respect to areas with no immune cells (arrowheads; see 
Fig. S2). (E–G) Consecutive tissue sections showing that RhoB 
is preferentially expressed in small vessels positive for smooth 
muscle actin (SMA) and negative for the NG2 proteoglycan. 
(H and I) RhoB staining in sinusoids from a control liver (H) 
and hepatitis B virus–infected liver (I). Bars: (A, B, and E–I) 
100 µm; (A, inset, and C and D) 10 µm.
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Figure 3. RhoB negatively regulates endothelial barrier recovery after acute contraction human endothelial cells. (A and B) Single knockdown of RhoA, 
RhoB, and RhoC has no effect on the barrier function of TNF-stimulated HUV ECs. (A) Absolute TEER of HUV ECs transfected with the indicated siRNA oligo-
nucleotides for 72 h or incubated with TNF for 7 h. Control cells were incubated with 5 µm Y-27632 for 30 min before TNF stimulation when specified. Dis-
continuous line marks the basal resistance values in empty electrodes. *, P < 0.5. RhoBp, RhoB pool. (B) Permeability to dextran-FITC of siRNA-transfected 
HUV ECs plated on transwells for 48 h and stimulated with TNF. No statistically significant differences were found in permeability values between siControl 
and siRho-transfected cells. (C) Left graph shows changes in TEER during thrombin-induced acute contraction in cells pretreated with TNF for 7 h as in 
A. Mean ± SEM from at least three independent experiments. (right graph) Percentage of maximum contraction with respect to siControl cells during acute 
contraction (0.5 h of thrombin stimulation) and barrier recovery (1.2 h of thrombin stimulation). A total of 5 µM Y-27632 was added 30 min before throm-
bin stimulation when indicated. Mean + SEM from at least three independent experiments. *, P < 0.02; **, P < 0.007; ***, P < 10−3. (D) Percentage of 
maximum contraction with respect to siControl cells during acute contraction (C.) and barrier recovery (R.) in HUV ECs pretreated with TNF between 18 and 
20 h. ***, P < 2.2 × 10−5. (E) Permeability to dextran-FITC was performed as in B but analyzed during the time of barrier recovery after acute contraction 
induced by thrombin. (F) Staining for β-catenin and F-actin in TNF-pretreated HUV ECs stimulated during the recovery phase after thrombin. Empty spaces 
between cells were identified by automated image analysis (mask). β-Catenin staining at cell borders was quantified by semiautomated image processing 
in five different experiments. *, P ≤ 0.046. Bar, 20 µm. (G) Percentage of maximum contraction with respect to siControl cells during acute contraction 
and the subsequent recovery induced with thrombin in HUV ECs not previously stimulated with TNF. *, P = 0.047; **, P = 0.009; ***, P = 9.4 × 10−5.  
(H) Changes in TEER during thrombin-induced acute contraction in HDM VECs pretreated with TNF for 7 h (left). Mean ± SEM from at least three indepen-
dent experiments. Percentage of maximum contraction with respect to siControl1 during contraction and barrier recovery in HDM VECs (right). *, P ≤ 0.05; 
**, P < 0.01; ***, P < 0.005. (I) TNF-pretreated HDM VECs were fixed after 2.5 h of thrombin stimulation (recovery phase) and stained for β-catenin 
and F-actin. β-Catenin staining at cell borders was quantified as in F. *, P < 0.05; **, P < 0.01. Bar, 10 µm. Mean + SEM of at least three experiments.
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RhoB sustains acute contraction and 
delays endothelial barrier recovery in  
TNF-stimulated HUV ECs
Inflammation and coagulation influence each other in chronic 
inflammatory pathologies such as Crohn’s disease, ulcer-
ative colitis, and multiple sclerosis (Scaldaferri et al., 2011; 
Roshanisefat et al., 2014). Thrombin-mediated activation 
of protease-activated receptors is a paradigm of acute Rho- 
controlled actomyosin-dependent contraction that disrupts en-
dothelial integrity and causes vascular dysfunction in a range 
of proinflammatory diseases (Croce and Libby, 2007; Boris-
soff et al., 2009). Thus, we next investigated whether TNF–
up-regulated RhoB expression contributes to acute barrier 
disruption induced by thrombin in an inflammatory context. The 
barrier function of TNF-pretreated, single siRNA–transfected 
HUV ECs was analyzed after thrombin stimulation. Before 
thrombin, no significant changes in TEER were observed in 
these cells (Fig. 3 A). Thrombin induced a rapid and acute de-
crease in TEER, followed by a slower recovery to initial values 
of resistance (Fig. 3 C, left graph). Control siRNA or siRNA 
targeting RhoA and RhoC had no major effect on TEER. RhoB 
was silenced with two individual siRNAs, as well as with a pool 
of four different and specific RhoB siRNAs designed to reduce 
off-target effects (Fig. S3, A–D). The three sets of RhoB siRNA 
inhibited the initial reduction of TEER 30 min after thrombin 
stimulation (maximum contraction) and significantly shortened 
the subsequent monolayer recovery time, quantified by measur-
ing TEER recovery 72 min after thrombin stimulation (Fig. 3, C 
[right] and D; and Fig. S3, A–D). This was similar to the effect 
that we and others had observed by ROCK inhibition (Fig. 3 C; 
Kawkitinarong et al., 2004; Fernández-Martín et al., 2012), 
although Y27632 had a stronger effect on initial contraction. 
RhoB-depleted cells also had reduced permeability when an-
alyzed by transwell permeability assays during the period of 
time between acute contraction and barrier recovery (Fig. 3 E). 
RhoB knockdown increased cell–cell junction integrity, which 
was addressed by localizing β-catenin after thrombin stimula-
tion (Fig. 3 F, right graph). RhoB knockdown had a specific but 
milder effect on endothelial barrier reformation in HUV ECs not 
previously treated with TNF and, therefore, with lower levels 
of RhoB protein (Fig. 3 G). Finally, in HDM VECs, single Rho 
knockdown induced a moderate decrease in acute contraction, 
whereas barrier recovery was also accelerated by RhoB deple-
tion and at less extent, by RhoC depletion (Fig. 3 H and Fig. S3, 
A and D). HDM VEC barrier reformation was increased upon 
RhoB knockdown when analyzed by confocal analysis of cell–
cell junction integrity (Fig. 3 I), indicating that RhoB also plays 
a specific role in prolonging thrombin-induced barrier disrup-
tion in microvascular endothelial cells.
Thrombin stimulation activated RhoA, RhoB, and RhoC 
with comparable kinetics in HUV ECs pretreated with TNF 
(Fig. 4, A and B). Because expression levels were also similar 
(Fig. S1 F), we hypothesized that RhoB specificity on prolong-
ing cell contraction could be caused by the differential regula-
tion of downstream signaling pathways involved in this process. 
Active Rho can increase myosin light chain (MLC) phosphory-
lation through ROCK activation (Riento and Ridley, 2003). This 
promotes nonmuscle myosin II isoforms to interact with F-actin 
and to increase actomyosin contractility. Depletion of RhoA, 
but not RhoB, reduced MLC phosphorylation 2 min after 
thrombin stimulation (Fig. 4, C and D). Paxillin is a scaffolding 
protein that regulates focal adhesion (FA) stability and becomes 
phosphorylated upon interaction with other FA components, 
including FA kinase, reported to be essential for endothelial 
barrier restoration after thrombin stimulation (Knezevic et al., 
2009). Single RhoA and RhoB knockdown similarly reduced 
paxillin phosphorylation in Tyr-31, which suggested no selec-
tive role for RhoB in regulating this protein (Fig. 4, C and E). 
These results suggest that RhoB’s specific role in endothelial 
barrier recovery does not involve signaling to MLC and paxillin 
and that partial inhibition of MLC activation is not sufficient to 
prevent thrombin-induced contraction.
RhoB prevents endothelial plasma membrane 
extension after acute contraction
We observed that the expression of a constitutive active mutant 
RhoB-V14 had no effect on cell–cell junction integrity even 
though cell-spread area was significantly reduced (Fig.  5  A). 
This led us to hypothesize that the role of RhoB in throm-
bin-mediated endothelial remodeling may be independent of 
the reannealing of cell–cell junctions. Indeed, the kinetics of 
thrombin-induced contraction and subsequent spreading in 
TNF-pretreated subconfluent HUV ECs were consistent with 
those of barrier disruption and reformation in confluent cells, 
indicating that cell contraction and recovery are independent of 
the cell–cell junctions (Figs. 3 C and 5 B). Confocal analysis 
revealed that RhoB knockdown slightly increased cell area of 
subconfluent HUV ECs before thrombin stimulation and clearly 
accelerated cell respreading after thrombin-mediated con-
traction (Fig. 5 C). 60 min after thrombin stimulation, RhoB- 
depleted cells recovered their initial spreading area, whereas 
siControl cells had only 60% of their area before stimulation 
(Fig. 5 C). In contrast, RhoB-V14 expression reduced cell re-
spreading (Fig. 5 D), suggesting that RhoB negatively regulates 
the membrane extension that follows acute contraction. A sim-
ilar increase in cell area was observed in RhoB-depleted sub-
confluent HDM VECs at the time of cell respreading (Fig. 5 E).
Time-lapse confocal analysis of GFP-RhoB revealed that 
the number of RhoB-positive vesicles moving between an en-
dosomal-like perinuclear compartment and the plasma mem-
brane more than doubled during membrane reextension after 
thrombin-induced contraction, compared with cells before con-
traction (Fig. 6, A–C; and Videos 1 and 2). This increase was 
detected in both directions, from the perinuclear compartment 
toward the plasma membrane (Fig.  6  B) as well as for vesi-
cles that emerge from the plasma membrane and follow inward 
movement (Fig. 6 C). In addition, the analysis of endogenous 
RhoB distribution by superresolution microscopy revealed that 
RhoB was not evenly distributed but formed nanoclusters in the 
endosomal vesicles (Fig. 6 D), which were modestly reduced 
in response to thrombin (Fig. 6 E). To identify the intracellular 
localization of RhoB, we analyzed the distribution of endoge-
nous RhoB with respect to different endosomal markers. RhoB 
has been localized in an early endosomal compartment (Fer-
nandez-Borja et al., 2005; Kroon et al., 2013). TNF-stimulated 
HUV ECs were loaded with transferrin-TRI TC for 5 min before 
performing a time course of thrombin stimulation. A small frac-
tion of RhoB vesicles overlapped with transferrin suggesting a 
partial localization of RhoB in early endosomes (Fig. 6 F and 
not depicted). This was confirmed by colocalization analysis in 
cells expressing the early endosomal GFP-Rab5, in which some 
vesicles overlapped with RhoB at any time of thrombin stimu-
lation (Fig. 6 F and not depicted). The partial overlap between 
RhoB and transferrin was reduced in cells stimulated with 
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thrombin and simultaneously loaded with transferrin for 1.2 h, 
which suggests that RhoB does not significantly localize in 
an endosomal-recycling compartment during barrier recovery 
(Fig. 6 F). RhoB colocalization with recycling GFP-Rab11 was 
also minor at any time of thrombin stimulation (Fig. S5 A and 
not depicted). Similarly, the colocalization of RhoB vesicles 
with the fast-recycling Rab4 and the protein epsin homology do-
main 1 (EHD-1), which regulates specific trafficking pathways 
in the recycling system (Goldenring, 2015), was negligible (Fig. 
S5 A). In contrast, RhoB perinuclear clusters and vesicles co-
localized with the late endosomal marker Rab7, suggesting that 
RhoB distributes along the endocytic route between early and 
late endosomes, but mainly in this latter compartment, as previ-
ously described for epithelial cell lines (Wherlock et al., 2004).
RhoB negatively regulates Rac1 trafficking 
from the endosomal compartment to the 
plasma membrane
The Rho GTPase Rac1 plays a central role in regulating plasma 
membrane extension (Price et al., 1998) and endothelial per-
meability and cell–cell junction stabilization (Daneshjou et al., 
2015). We investigated whether RhoB regulates Rac1-mediated 
cell spreading. Exogenous expression of Rac1 was sufficient 
to induce membrane extensions and increase the cell-spread 
area HEK293 cells. Interestingly, coexpression of RhoB-V14 
impaired Rac1-induced protrusions in cells expressing similar 
levels of exogenous Rac1 (Fig. S5 B). Thus, active RhoB im-
pairs the plasma membrane extension after thrombin stimula-
tion, but also upon Rac1 overexpression. The extension of the 
plasma membrane during cell migration requires Rac trafficking 
between the plasma membrane and a Rab5-positive endosomal 
compartment, in which Rac encounters and recycles with gua-
nine nucleotide exchange factors toward the plasma membrane 
to form F-actin–mediated protrusions (Palamidessi et al., 2008). 
We analyzed the distribution of Rac1 in endothelial cells and 
found it to be localized at the plasma membrane and in internal 
vesicular clusters (Fig. 7 A). Expression of constitutively active 
RhoB-V14 significantly reduced Rac1 localization in the plasma 
membrane, even in cells that were properly spread and adhered 
to the substrate (Fig. 7 A). In contrast, reduction of RhoB expres-
sion increased Rac1 localization at cell borders (Fig. 7 B). More-
over, Rac1 and RhoB-V14 clearly colocalized in a perinuclear 
vesicular compartment positive for Rab7 (Fig. 7, C and D) and in 
a compartment positive for Rab5 (Fig. 7, C and E). The localiza-
tion of active RhoB-V14 in Rab5-positive endosomes increased 
with respect to exogenous or endogenous RhoB (Figs. 6 F and 7 
E). Endogenous RhoB staining also overlapped with Rac1 in an 
intracellular compartment in confluent HUV ECs (Fig. 7 F) and 
in HDM VECs (Fig. S5 C) pretreated with TNF. During barrier 
reformation after thrombin stimulation, Rac1 and RhoB partially 
colocalized in vesicles, but not in lamellipodial-like extensions 
(Fig. 7 F). Therefore, RhoB activity reduces Rac1 presence at the 
cell border and favors Rac1 intracellular localization.
However, superresolution confocal microscopy suggested 
that Rac1 and RhoB accumulate in different domains in intra-
cellular vesicles (Fig.  7  G). Accordingly, no association was 
detected between Rac1 and RhoB in coimmunoprecipitation 
experiments and in the pull-down assays performed to ana-
lyze Rac1 and RhoB activity (unpublished data). We then in-
vestigated whether RhoB and Rac1 could be in proximity and 
therefore establish transient but undetectable interactions. We 
generated a construct of RhoB conjugated from its N-terminal 
domain to the mutant of biotin-ligase BirA, which adds biotin to 
proteins in its proximity, and performed BioID assays (Fig. 7 H; 
Roux et al., 2012). GFP-Rac1 coexpressed with RhoB-BirA 
was detected in pull-down assays performed with neutravidin to 
purify biotinylated proteins (Fig. S5 D). Exogenous biotin was 
required for GFP-Rac1 biotinylation, whereas GFP alone was 
Figure 4. Effect of RhoA and RhoB on myo-
sin light chain and paxillin phosphorylation. 
(A) Pull-down assays of RhoA, RhoB, and 
RhoC during acute contraction induced with 
thrombin in HUV ECs pretreated with TNF for 
8  h. Graphs show active Rho normalized to 
total Rho levels from three different experi-
ments. (B) TNF-pretreated, siRNA-transfected 
HUV ECs were stimulated with thrombin for the 
indicated times and immunoblotted for the in-
dicated proteins. (C and D) Quantification of 
phosphorylation of the indicated proteins from 
at least three experiments. **, P < 0.005.
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not biotinylated (Fig. S5 E). Overexpression of RhoB-BirA in-
duced a reduction of GFP-Rac1 expression compared with cells 
expressing only GFP-Rac1 (Fig. S5 D and Fig. 7 H). We then 
adopted a complementary strategy and immunoprecipitated 
Rac1 in the presence or absence of BirA-RhoB. Cells express-
ing BirA-RhoB induced biotinylation of several proteins, which 
were detected by blotting with streptavidin conjugated to perox-
idase (Fig. 7 H). At least four biotinylated proteins were found 
in the GFP-Rac1 immunoprecipitates (Fig. 7 H, asterisks). Two 
of these proteins were coincident with those detected by West-
ern blot using anti-Rac1 antibody, which corresponded to the 
molecular weights of GFP-Rac1 and endogenous Rac1, which 
coimmunoprecipitated with GFP-Rac1 (Fig. 7 H).
Consistent with the role of RhoB in Rac1 localization, 
time-lapse confocal microscopy revealed that RhoB knock-
down reduced the number of Rac1 vesicles moving toward and 
away from the plasma membrane and induced the accumulation 
of Rac1 at the periphery (Fig. 7, I and J; and Videos 3 and 4). 
Together, these results indicate that active RhoB transiently co-
localizes with and retains Rac1 in an endosomal compartment, 
preventing it localizing to the plasma membrane.
RhoB inhibits endothelial barrier 
restoration by controlling Rac1 activity 
and trafficking
Simultaneously with RhoA and RhoB activation, Rac1 activ-
ity decreases within the first minutes of thrombin stimulation 
and subsequently recovers (Fig. 8 A). Pull-down assays during 
a time course of thrombin stimulation showed an increase in 
Rac1 activity in RhoB-depleted HUV ECs with respect to con-
trol cells at the time of cell respreading (Fig. 8 A). Rac1 activ-
ity did not change in RhoA-depleted cells (Fig. 8 B). Transient 
inhibition of Rac activity with NSC23766 during the time of 
barrier recovery abolished the effect of RhoB siRNA (Fig. 8, 
C and D), suggesting that Rac mediates the role of RhoB in 
sustaining cell contraction in endothelial monolayers. Next, 
we addressed whether Rac1 trafficking is involved in barrier 
restoration. Brefeldin A is a lactone antibiotic that inhibits an-
terograde intracellular transport and induces tubulation of the 
endosomal system (Lippincott-Schwartz et al., 1991), mon-
ensin is a ionophore that increases the pH of acidic endoso-
mal vesicles and blocks their transport (Chapman and Munro, 
1994), and dynasore impairs vesicle endocytosis and recycling 
Figure 5. RhoB regulates cell area recovery 
after acute contraction independently of cell–
cell contacts. (A) HA-RhoBV14 has no effect on 
endothelial cell–cell junctions. HA-RhoBV14 
was expressed for 48  h in confluent HUV 
ECs. Bottom images show enlargements of 
squared areas from HA-RhoBV14 transfected 
(1) and untransfected cells (2). Bar, 20 µm. 
(B) Time-lapse microscopy of subconfluent 
HUV ECs stimulated with thrombin. Cell areas 
were quantified from individual frames taken 
at different times (right graph). Graph shows 
the mean + SEM of at least 10 cells per ex-
periment from three different experiments. Bar, 
20 µm. (C) siRNA-transfected, TNF-pretreated 
HUV ECs were stimulated with thrombin for the 
indicated times, and then fixed and stained for 
F-actin and RhoB. Right graph quantifies cell 
area. Mean + SEM from three different experi-
ments. 50 cells per experiment. RhoB-depleted 
cells recover their initial area (respreading) 
at 60 min poststimulation. *, P < 0.04; **, 
P < 0.03. (D) HUV ECs expressing GFP or 
HA-RhoBV14 for 24  h were stimulated with 
thrombin for 60 min, stained for F-actin and 
HA-RhoBV14, and the cell area quantified. 
Graph shows the mean + SEM of at least 10 
cells per experiment from three different exper-
iments. **, P = 0.001. (E) siRNA-transfected, 
TNF-pretreated HDM VECs were stimulated 
with thrombin for 2.5  h (respreading), and 
then fixed and stained for F-actin and RhoB. 
Graph shows the mean + SEM from at least 50 
cells per experiment, from three different exper-
iments. *, P ≤ 0.05; **, P < 0.01. Bar, 10 µm.
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Figure 6. Thrombin increases RhoB vesicular trafficking and reduces vesicular RhoB nanoclusters during cell area recovery. (A–C) GFP-RhoB was ex-
pressed in HUV ECs for 24 h. TNF-pretreated cells were left unstimulated (−) or stimulated with thrombin for at least 60 min and analyzed by time-lapse 
confocal microscopy at 20-s intervals during a 20-min period. Bars: 20 µm; (zoom) 2 µm. (B) RhoB-positive vesicles emerging from a perinuclear com-
partment toward the plasma membrane were tracked and the tracks plotted with a common origin. 12 cells per condition were analyzed. Bar, 2 µm. 
(C) RhoB-positive vesicles emerging from the plasma membrane toward a perinuclear compartment were tracked and the tracks plotted with a common 
origin. 12 cells per condition were analyzed. Bar, 2 µm. (D) STO RM microscopy to generate a superresolution image of RhoB in perinuclear vesicles in 
TNF-pretreated HUV ECs. Bar, 2 µm. (E) STO RM images of RhoB clusters in intracellular vesicles during thrombin stimulation in TNF-pretreated HUV ECs. 
Pixels of the reconstruction are shown. RhoB clustering was measured by calculating the Ripley´s K-function. K function for clusters from at least five images 
in three different experiments was calculated. ***, P < 0.005. Bar, 2 µm. (F) Localization of endogenous RhoB in TNF-pretreated HUV ECs previously 
incubated with transferrin-TRI TC for 5 min to localize early endosomes and for 1.2 h to localize recycling endosomes during barrier recovery. Localization 
of endogenous RhoB upon expression of the indicated Rab-GFP proteins. RhoB clearly colocalizes with Rab7-positive vesicles (arrowhead) in a perinu-
clear compartment (bracket).
o
n
 Septem
ber 27, 2016
D
ow
nloaded from
 
Published May 2, 2016
JCB • Volume 213 • NumBer 3 • 2016394
Figure 7. RhoB regulates endothelial Rac1 localization and trafficking. (A) mCherry-Rac1 and HA-RhoBV14 were expressed in EA.hy.926 cells and 
stained for HA epitope and F-actin. Right graph quantifies relative mCherry-Rac1 localization at cell border and shows the mean + SEM of at least 10 
cells per experiment quantified in three different experiments. Arrowheads point to mCherry-Rac1 at the plasma membrane. RhoBV14 reduces Rac1 bor-
der localization even in cells correctly spread on the substrate. ***, P = 5.30 × 10−5. (B) HUV ECs were transfected with the indicated siRNAs and then 
mCherry-Rac1 expressed during the last 24 h. TNF-pretreated cells were stimulated with thrombin for 60 min and fixed, and mCherry-Rac1 was quantified 
as in A. Graph shows the mean + SEM of four experiments. *, P = 0.026; ***, P = 5 × 104. (C) mCherry-Rac1 colocalizes with active RhoB in intracellular 
compartments. mCherry-Rac1 and HA-RhoBV14 were expressed in EA.hy.926 cells. Significant colocalization was observed in a perinuclear compart-
ment (1) and in a dispersed vesicular pattern (2; arrowheads). (D and E) HA-RhoBV14 and mCherry-Rac1 co localize in Rab5-GFP (D) and Rab7-FGP– 
positive (F) compartments. Right images show an enlargement of the squared area. (F) Endogenous RhoB and mCherry-Rac1 partly colocalize in a vesicular 
compartment in confluent, TNF-pretreated HUV ECs stimulated or not with thrombin for 30 and 72 min (arrowheads). mCherry-Rac1 is also localized in 
nascent membrane protrusions (arrowhead). Bars: (A–F) 20 µm; (D–F, enlarged areas) 5 µm. (G) STED confocal images of Rac1 clusters, which appear 
different to those of RhoB in the same vesicle (arrowhead). Bar, 4 µm (H) BioID assay with BirA-RhoB. HEK293 cells were transfected with BirA-RhoB and 
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by inhibiting dynamin-2, a GTPase involved in clathrin-coated 
vesicle formation (Macia et al., 2006). We found that brefeldin 
A, monensin, and dynasore decreased barrier reformation and 
caused intracellular accumulation of Rac1 (Fig.  9, A, B, and 
E). In addition, brefeldin A reduced the movement of Rac1- 
positive intracellular vesicles (Fig. S5, F and G; and Videos 5 
and 6). Conversely, hepatocyte growth factor (HGF) induces 
Rac1 translocation from the Rab5 compartment to the plasma 
membrane in nonendothelial cells (Palamidessi et al., 2008). 
Exposure of thrombin-stimulated endothelial cells to HGF at 
the initiation of monolayer recovery increased Rac1 translo-
cation to the plasma membrane and, accordingly, accelerated 
barrier function recovery (Birukova et al., 2007; Fig. 9, C-E), 
similar to the effect of RhoB knockdown. Together, our results 
indicate that RhoB negatively regulates the endothelial mem-
brane extensions required for barrier reformation, which are 
controlled by Rac1 trafficking.
Finally, we had previously shown a milder effect of RhoB 
siRNA on endothelial barrier recovery in the absence of long-
term TNF stimulation, in which RhoB is expressed at low levels 
(Fig. S5 A). NSC23766 moderately delayed barrier reformation 
in unstimulated cells but caused strong and sustained inhibition 
of barrier reformation at least 4 h after thrombin stimulation in 
TNF-pretreated cells (Fig. 9 F). These results suggest that RhoB 
and Rac1 contribute to endothelial barrier recovery primarily in 
an inflammatory context.
Discussion
To investigate the molecular mechanisms mediating endothe-
lial barrier dysfunction, we searched for new proteins whose 
expression is modulated by TNF. We found that TNF and IL-1β 
increased RhoB mRNA and protein expression in HDM VECs 
and HUV ECs, which is comparable to what was recently re-
ported in HUV ECs (Kroon et al., 2013). In addition, RhoB is 
highly expressed in some vessels from chronically inflamed 
tissues, such as those in lesions from patients with Crohn’s 
disease, and in leaky and specialized vessels, such as hepatic 
sinusoids. RhoB belongs to the RhoA subfamily, which reg-
ulates common effectors that are potential targets for treating 
proinflammatory and prothrombotic diseases and ameliorating 
endothelial dysfunction (Shi and Wei, 2013). For this reason, 
we undertook a detailed analysis of the role of each subfamily 
member in this regulation in human primary endothelial cells. 
Our functional analyses by transient gene silencing reveal first 
that RhoA, RhoB, and RhoC play additive roles in maintaining 
homeostatic barrier function and junction distribution and re-
dundant or compensatory roles in regulating F-actin levels. The 
additive roles of RhoA and RhoB in endothelial barrier function 
have also been observed by expressing dominant-negative (DN) 
forms of RhoA and RhoB (Wojciak-Stothard et al., 2012). Sin-
gle expression of the DN mutant of RhoA significantly inhib-
ited the increase in pulmonary endothelial permeability noted 
under hypoxic conditions, whereas no significant effect was 
detected upon expression of DN RhoB. Coexpression of both 
DN mutants increased their inhibitory effect, suggesting that 
RhoB cooperates with RhoA in controlling endothelial barrier 
disruption during hypoxia (Wojciak-Stothard et al., 2012). DN 
Rho proteins inhibit endogenous Rho proteins by sequestering 
upstream GTP exchange factors, so their DN effect is extended 
to those Rho proteins that share these activators (Feig, 1999). 
Hence, their specificity with respect to the other two members 
of the family may be reduced compared with gene-silencing–
based strategies. Our data indicate that among those additive 
effects, RhoC plays a main role in controlling constitutive endo-
thelial barrier function whereas RhoB seems to have a predom-
inant role in mediating acute contraction in endothelial cells 
exposed to inflammatory mediators. The analyses of a knock-
out mouse model of RhoB and the gene silencing of RhoC in 
human endothelial cells have previously shown the importance 
of RhoB and RhoC for other endothelial functions related to 
barrier function such as angiogenesis (Gerald et al., 2013; Ho-
eppner et al., 2015), whereas the study of the vascular-specific 
RhoA knockout mouse indicate that this GTPase is essential for 
mediating the permeability increase in response to histamine 
(Mikelis et al., 2015). However, no comparative studies of the 
relative expression and contribution of other RhoA subfamily 
members have been reported in these studies.
Thrombotic factors can cause endothelial contraction 
leading to a disruption of vascular integrity during inflamma-
tion (Beckers et al., 2010). Whereas contraction can be partially 
inhibited by inhibitors that target the common downstream 
effector ROCK (Komarova et al., 2007; Fernández-Martín et 
al., 2012), we have identified a novel and specific function for 
RhoB as a negative regulator of barrier reformation through the 
control of Rac1 localization and activity. This negative regula-
tion occurs in cytokine-pretreated vascular and microvascular 
endothelial cells, but it is also detected in endothelial cells that 
are not pretreated with cytokines in which the effect of RhoB 
siRNA is milder than in TNF-stimulated cells, consistent with 
the relatively low level of expression of RhoB in the absence of 
inflammatory stimulation. Therefore, on the one hand, RhoB 
has similar roles to those of RhoA and RhoC, for instance, in 
regulating F-actin, whereas RhoB specifically mediates endo-
thelial barrier reformation and controls Rac1 intracellular traf-
ficking. This dual role might reflect the fact that RhoB is the 
only member of this subfamily that undergoes alternative lipid 
modifications in its C-terminal domain. Similar to RhoA and 
RhoC, a subset of RhoB is geranylgeranylated and localizes at 
the plasma membrane in its active form, whereas another sub-
set of RhoB molecules, but not of RhoA and RhoC molecules, 
is isoprenylated and palmitoylated, which specifically localizes 
that GTPase at the endosomal compartment (Wheeler and Rid-
ley, 2004; Pérez-Sala et al., 2009).
Rac1 targeting to the cell border from an endosomal com-
partment was found to be necessary to form actin-mediated 
plasma-membrane protrusions during cell migration, and HGF 
GFP-Rac1 when indicated. GFP-Rac1 was immunoprecipitated with anti-GFP antibodies. Biotinylated proteins were detected by blotting with streptavidin 
peroxidase (asterisks). IgG, isotype-specific antibody control. Coexpression of BirA-RhoB reduces GFP-Rac1 detection in the cell lysates. (I) mCherry-Rac1 
was expressed for 24 h in siRNA-transfected HUV ECs. TNF-pretreated cells were stimulated with thrombin between 60 and 100 min, and Rac1 vesicular 
movement was recorded at 15-s intervals during a minimum of 5 min. Arrowheads point to mCherry-Rac–positive vesicles. In the top row of images, one 
vesicle divides in two and merges again. Bars: 20 µm; (zoom) 2 µm. (J) Each graph represents the tracks of 15 vesicles per cell, in eight cells, from three 
different experiments. Vesicle tracks were plotted with a common origin.
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stimulated this Rac translocation (Palamidessi et al., 2008). In-
terestingly, we and others have found that HGF accelerates en-
dothelial barrier recovery (Birukova et al., 2007, 2008), which, 
as we show here, is associated with increased Rac1 localization 
at the plasma membrane. These data indicate that Rac1 traf-
ficking in the endothelium after thrombin-mediated acute con-
traction is comparable to Rac1 translocation in migrating cells 
and is regulated by endosomal RhoB. RhoB also regulates Rac1 
negatively in cancer cell invasion (Bousquet et al., 2009) and 
positively in platelet-derived growth factor stimulation (Huang 
et al., 2011). RhoB has been proposed to link endosomal vesi-
cles to actin filaments through its effector formins mDia1 and 
mDia2 (Sandilands et al., 2004; Fernandez-Borja et al., 2005; 
Wallar et al., 2007). Constitutively active RhoB or mDia mu-
tants reduce the velocity of intracellular vesicles, probably by 
increasing the association of endosomal carriers with actin fil-
aments (Fernandez-Borja et al., 2005; Wallar et al., 2007). We 
have found that RhoB depletion increases Rac1 at cell borders 
and reduces the trafficking of remaining Rac1 vesicles, sug-
gesting that RhoB controls Rac1 vesicular movement toward 
the cell border and, hence, toward nascent cell–cell junctions. 
Active RhoB also accumulates with Rac1 in a Rab7-positive en-
dosomal compartment, which suggests that RhoB activity may 
not only control vesicular dynamics but also divert recycling 
Rac1 to a late-endosomal compartment, thereby delaying the 
return to the plasma membrane (Fig. 9 G).
In an inflammatory context, Rac1 promotes extension of 
ventral lamellipodia to repair microwounds caused by adhered 
leukocytes undergoing diapedesis (Martinelli et al., 2013). 
However, the role of vesicular trafficking and Rac1 recycling 
has not yet been addressed for this type of membrane exten-
sion. The parallels between the signaling machinery mediating 
membrane extension during migration and barrier formation 
can be also found upstream of Rac1. Platelet-derived growth 
factor or HGF induces Rac1 translocation to endosomes where 
this GTPase encounters the GTP exchange factor Tiam1 during 
recycling to form actin-based migratory protrusions. In the en-
dothelium, Tiam1 contributes to Rac1 activation in response to 
various barrier-stabilizing mediators (Schlegel and Waschke, 
2014). Indeed, a close connection between lamellipodia and 
maturation of cell–cell junctions has recently been described 
(Abu Taha et al., 2014).
Figure 8. Rac1 activity is regulated by RhoB and is required for endothelial barrier recovery after acute contraction. (A and B) siRNA-transfected HUV ECs 
were pretreated with TNF and stimulated with thrombin for the indicated times. Cells were lysed and pull-down assays performed to detect (active) Rac1-
GTP levels. (A) Effect of RhoB siRNAs on Rac1 activation. Bottom graph shows active Rac1 normalized to total Rac1 levels. Mean + SEM from al least 
three different experiments measuring. *, P ≤ 0.05. (B) Effect of RhoA siRNA on Rac1 activation. Right graphs show the mean + SEM from three different 
experiments measuring the absolute levels of Rac1-GTP (active) and total Rac1. ***, P = 8.85 × 10−6. (C and D) Rac inhibition impairs barrier recovery 
in RhoB-transfected cells. siRNA transfected, TNF-pretreated HUV ECs were stimulated with thrombin. 20 min after stimulation, 100  µM Rac inhibitor 
NSC23766 was added when indicated. (C) Cells were fixed and stained for the indicated proteins 72 min after stimulation. Automated image analysis 
was applied to detect empty areas in the cell monolayer (mask). Bar, 20 µm. (D) Analysis of TEER at 30 and 72 min after stimulation. Graph shows the 
mean + SEM of five different experiments. *, P ≤ 0.036.
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Figure 9. Rac trafficking is essential for endothelial barrier recovery after thrombin stimulation. (A) Inhibitors of intracellular trafficking delay barrier 
recovery. TNF-pretreated HUV ECs were stimulated with thrombin to induce acute contraction, and after 20 min, 10 µM/l monensin and 10 µg/ml brefel-
din A or 60 µM/l of the dynamin inhibitor dynasore was added when indicated. Changes in TEER were recorded and quantified at the indicated times. 
Graph shows the mean + SEM from four independent experiments. *, P < 0.031. (B) TNF-pretreated HUV ECs stimulated with thrombin for 72 min in the 
presence or absence of the indicated inhibitors and stained for β−catenin and F-actin. Automated image analysis was applied to detect empty areas (mask). 
Bar, 20 µm. (C) HGF accelerates endothelial barrier reformation in TNF-pretreated endothelial cells. Relative contraction levels after thrombin stimulation at 
the indicated times in the presence or absence of 30 ng/ml HGF added 20 min after stimulation. Graph shows the mean + SEM of eight different experi-
ments. **, P = 0.006. (D) Cells were treated as in C, fixed 72 min after thrombin stimulation, and stained for the indicated proteins. Automated image anal-
ysis was applied to detect empty areas in the cell monolayer (mask). Bar, 20 µm. (E) Effect of dynasore and HGF on mCherry-Rac1 localization. EA.hy.926 
cells were transfected with mCherry-Rac1, pretreated with TNF, and stimulated with thrombin alone or in combination with dynasore and HGF as in B and 
D, respectively. Cells were fixed and stained for F-actin. Bar, 20 µm. (F) TNF increases endothelial sensitivity to Rac inhibition during endothelial barrier 
reformation. HUV ECs were treated with or without TNF, and the effect of NSC23766 on endothelial barrier recovery upon acute contraction was measured 
by electric cell substrate impedance sensing; T, thrombin. The mean + SEM from three independent experiments is shown. *, P = 0.011. (G) A model for the 
endocytic control of Rac1 translocation to the plasma membrane through RhoB during barrier restoration. Rac1 shuttles between early endosomal compart-
ment and the plasma membrane but is also delivered to a RhoB-positive late endosomal compartment. High RhoB levels displace Rac1 to endosomes and 
prevent Rac1 recycling during barrier recovery. Low RhoB activity favors Rac1 recycling to the cell border, accelerating barrier recovery after contraction.
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The effect of Rac inhibition on barrier reformation be-
tween TNF-treated and resting endothelial cells is markedly 
different. Other researchers have reported that TNF causes 
a striking delay in endothelial barrier formation after throm-
bin-induced contraction (Paria et al., 2004). We propose that 
endothelial barrier disruption in response to long-term exposure 
to inflammatory cytokines such as TNF involves not only an 
increase in permeability to cells and small molecules but also 
a decrease in the “robustness” of the endothelial monolayer by 
reducing the ability of endothelial cells to reform the mono-
layer upon disruption. This would make the endothelium more 
prone to disruption by injury or edemagenic and coagulatory 
challenges that arise in different inflammatory contexts, particu-
larly in chronic diseases such as Crohn’s or hepatitis. Targeting 
negative regulators of barrier formation expressed in such con-
texts such as RhoB may help preserve endothelial and vascular 
integrity in inflammatory pathologies.
Materials and methods
Materials
Mouse monoclonal anti–VE-cadherin (catalog number 610252), mouse 
anti-Paxillin (catalog number 610051), and mouse anti-Rac1 (cata-
log number 610650) were purchased from BD. Rabbit anti–ICAM-1 
(Sc-7891), rabbit anti-MLC (sc-15370), rabbit anti–ERK-1/2 (sc-94), 
mouse anti-RhoA (sc-418), and rabbit anti-RhoB (sc-180) for Western 
blot, mouse anti-RhoB (sc-8048) for immunofluorescence, and rab-
bit anti-RhoA/C (sc-179) were purchased from Santa Cruz Biotech-
nology, Inc. Rabbit anti-RhoC (D40E4) antibody was obtained from 
Cell Signaling Technology. Rabbit anti–β-catenin (C-2206) antibody 
was obtained from Sigma-Aldrich. Rabbit anti–p(T18/S19)MLC 
(44-260G) and anti–p(Y31) paxillin (44-720G) were obtained from 
Invitrogen. Goat anti–VCAM-1 (BBA19) was purchased from R&D 
Systems. Rat anti-HA (11867423001, clone 3F10), mouse anti-c-myc 
(11667149001, clone 9E10), and mouse anti-GFP (11814460001) 
were obtained from Roche. Phalloidin-TRI TC (P-1951) was obtained 
from Sigma-Aldrich. Anti-IgG mouse ATTO-647N was obtained 
from Sigma-Aldrich (50185). Alexa Fluor 647 Phalloidin (A-22287) 
and To-Pro-3(T-3605) were obtained from Invitrogen. Rac1 inhibitor 
NSC23766 (553502), dynamin inhibitor I (dynasore; CAS 304448–55-
3), and monensin (475895) were purchased from EMD Millipore. 
Brefeldin A (20350–15-6) was purchased from Sigma-Aldrich. Human 
HGF (PHG0254) was purchased from Gibco. Thrombin from human 
plasma (T6884) was purchased from Sigma-Aldrich. Recombinant 
human TNF and IL-1β was obtained from R&D Systems.
Plasmids, siRNA, and RT-qPCR analysis
Plasmid coding for HA-RhoB was from the UMR cDNA resource cen-
ter (University Missouri-Rolla). Plasmids coding for HA-RhoB-V14 
and GFP-RhoB were a gift from D. Pérez-Sala (Centro de Investiga-
ciones Biolgicas, Madrid, Spain)(Centro de Investigaciones Biológi-
cas, Madrid, Spain). To obtain a plasmid to express BirA-RhoB, a 
two-step procedure was followed. The sequence coding for GFP in the 
pEGFP-C1 expression vector was substituted by the BirA sequence. 
Then, the RhoB sequence was amplified by PCR and cloned between 
BglII and BamH1 restriction sites in the multicloning site. Plasmid 
coding for mCherry-Rac1 was a gift from F. Martín-Belmonte (Centro 
de Biología Molecular Severo Ochoa, Madrid, Spain). Plasmid from 
GFP-Rac1 was obtained from G. Bokoch (Scripps Research Institute, 
La Jolla, CA) through Addgene. Plasmid coding for GFP-Rab4 was 
from Gia Voeltz through Addgene. Plasmid coding for GFP-Rab5 was 
a gift from R.  Puertollano (National Institutes of Health, Bethesda, 
MD). Plasmids coding for GFP-Rab7 and GFP-Rab11 were a gift 
of M.A.  Alonso (Centro de Biología Molecular Severo Ochoa, Ma-
drid, Spain). Plasmids coding for GFP(emerald)-Rab7 and GFP(em-
erald)-Rab5 were also used and were obtained from M.  Davidson 
(Florida State University, Tallahassee, FL) through Addgene. The fol-
lowing siRNA oligonuceotides were obtained from the predesigned 
siGenome collection of Dharmacon (Vega et al., 2011): siControl1: 
nontargeting control, D-001210-01, 5′-UAG CGA CUA AAC ACA 
ICAA-3′; siControl2: nontargeting control, D-001810-03, 5′-AUG 
UAU UGG CCU GUA UUAG-3′; siRhoA1: D-003860-01, 5′-AUG 
GAA AGC AGG UAG AGUU-3′; siRhoA2: D-003860-02, 5′-GAA 
CUA UGU GGC AGA UAUC-3′; siRhoB1: D-008395-07, 5′-GCA 
UCC AAG CCU ACG ACUA-3′; siRhoB2: D-008395-09, 5′-CAU CCA 
AGC CUA CGA CUAC-3′, or D-008395-08, 5′-ACA CCG ACG UCA 
UUC UCAU-3′; siRhoC1: D008555-02, 5′-AUA AGA AGG ACC UGA 
GGCA-3′; siRhoC2: D008555-03. ON-TAR GETplus SMA RT pool 
siRNA, consisting of a pool of four siRNAs, was also from Dharmacon 
and consisted in the following sequences: siControlpool D-001810-
10, 5′-UGG UUU ACA UGU CGA CUAA-3′, 5′-UGG UUU ACA UGU 
UGU GUGA-3′, 5′-UGG UUU ACA UGU UUU CUGA-3′, and 5′-UGG 
UUU ACA UGU UUU CCUA-3′; SiRhoBpool L-008395: J008395-11, 
5′-GCA UCC AAG CCU ACG ACUA-3′; J008395-12, 5′-CAG AAC 
GGC UGC AUC AACU-3′; J008395-13, 5′-CGA CGA GCA UGU CCG 
CACA-3′; and J008395-14, 5′-AAG CAC UUC UGU CCC AAUG-3′. 
siRNA oligonucleotides were transfected with oligofectamine (Invitro-
gen; Fernández-Martín et al., 2012). Oligonucleotides for qPCR were 
from Sigma-Aldrich. One microgram of RNA from HUV ECs was 
subjected to reverse transcription with the High Capacity RNA-cDNA 
kit (Applied Biosystems). RT-qPCR was performed from the result-
ing cDNA in a thermocycler CFX 384 (Bio-Rad) using the SsoFast 
EvaGreen Supermix (Bio-Rad) and the forward and reverse primers, 
previously designed with Probefinder software (Roche), described in 
Table S2 and previously used in T cells (Bhavsar et al., 2013). Parallel 
qPCR for the reference genes β-actin and GAD PH was performed to 
normalize data from each point of stimulation. Triplicates from all the 
samples were run in parallel with non–reverse transcription controls 
for all the targets that yielded no detectable amplification. Unless indi-
cated otherwise, the quantification cycle (Cq) values were in the 20–24 
range, which indicates medium to high levels of these transcripts. Melt-
ing curves showed specific amplification in all cases except for RhoH. 
RhoH can be amplified with the same pair of oligonucleotides in T cell 
lines (Bhavsar et al., 2013). Relative quantification was performed with 
the software GenEx taking into account for corrections the efficiency 
of each pair of primers, the technical triplicates, and the contamination 
with genomic DNA, which was negligible. The relative quantification 
(2−ΔCq) was made with respect to the expression at time 0 of TNF stimu-
lation. Subsequently, these values were normalized again with respect a 
mean of the values of the reference genes. To do this, the stability of the 
candidate reference genes was evaluated with geNorm and Normfinder 
algorithms within Genex, and a combination of the two most stable was 
chosen to normalize the results.
Cell culture and transfection
HeLa and HepG2 cells were obtained from the American Type Cul-
ture Collection. These cells, EA.hy.926 cells and HBM EC cells were 
grown in DMEM supplemented with 10% FBS in an atmosphere of 
5% CO2/95% air. EA.hy.926 cells were a gift from C.J.S. Edgell (Uni-
versity of North Carolina, Chapel Hill, NC), and HBM ECs were a gift 
from B. Weksler (Cornell University, Ithaca, NY). Adult HDM VECs 
and the CAD MEC growth medium were from Tebu-Bio. HUV ECs 
were from Lonza. For siRNA transfection, HUV ECs and HDM VECs 
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were plated at subconfluence (105 cells on each well of a six-well dish) 
in EBM-2 medium (Lonza) with no antibiotics. The next day, cells 
were transfected by mixing 4  µl of oligofectamine (Invitrogen) with 
siRNA to a final concentration of 100 nM. At 24 h after transfection, 
cells were trypsinized and plated at confluence onto different dishes for 
parallel assays, such as permeability, adhesion, immunofluorescence 
or Western blotting (Aranda et al., 2013). Assays were performed 72 h 
after transfection. T-lymphoblasts were prepared from isolated human 
peripheral blood mononuclear cells. Nonadherent peripheral blood 
mononuclear cells were stimulated with 0.5% phytohemagglutinin for 
48 h and maintained in culture medium supplemented with interleu-
kin-2 as previously described (Reglero-Real et al., 2014). T lympho-
blasts were used in experiments after culturing for 7–12 d.
Pull-down assays to detect Rho activity
HUV ECs were transfected with the indicated siRNAs. After 72 h, cells 
were lysed and subjected to pull-down assays to analyze active, GTP-
loaded RhoGTPases as previously described (Cernuda-Morollón et al., 
2010; Fernández-Martín et al., 2012). In brief, cell lysates were incu-
bated at 4°C in assay buffer with 10 µg GST-fusion proteins immobi-
lized on GST-Sepharose beads. Active RhoA, RhoB, and RhoC were 
detected by pull-down with GST-rhotekin-RBD and active Rac1 with 
GST-PAK-PBD. Then, a fraction of the initial postnuclear supernatants 
and the final GST pull-down samples were subjected to SDS-PAGE in 
12% acrylamide gels under reducing conditions and transferred to Im-
mobilon-P membranes (EMD Millipore). After blocking with 5% non-
fat dry milk, 0.05% (vol/vol) Tween 20 in PBS, the membranes were 
incubated with the indicated antibodies, washed with PBS + 0.05% 
Tween 20, and incubated with the appropriate secondary antibodies 
coupled to HRP. After subsequent extensive washes, the membranes 
were developed using an enhanced chemiluminescence Western blot-
ting kit (ECL; GE Healthcare).
BioID assays
The expression vectors coding for BirA-RhoB and GFP-Rac were 
transfected in HEK293 cells with PEI (Sigma-Aldrich) 48 h before the 
assays. Cells were incubated with 50  µM biotin for 24  h, lysed and 
subjected to pull-down assay of biotinylated proteins with Neutravidin- 
Agarose (Thermo Fisher Scientific) as previously described (Roux 
et al., 2012; Rodríguez-Fraticelli et al., 2015;). Alternatively, cells 
were lysed in 25 mM Tris-HCl, pH 7.4, 1% Triton X-100, 150 mM 
NaCl, and 2 mM EDTA buffer containing protease inhibitors for 1 h 
at 4°C. After preclearing the postnuclear supernatant for 1 h with iso-
type-specific control immunoglobulin (Sigma-Aldrich) conjugated to 
protein G–Sepharose (Sigma-Aldrich), GFP-Rac was immunoprecipi-
tated with specific anti-GFP antibodies (Roche) conjugated to protein 
G–Sepharose for 12 h. In parallel, a control immunoprecipitation with 
the isotype-specific control immunoglobulin was performed. After ex-
tensive washes with the lysis buffer, immunoprecipitates were analyzed 
by Western blot with anti-Rac1 antibodies and by blot with streptavi-
din-peroxidase (Thermo Fisher Scientific).
Endothelial permeability and leukocyte transendothelial migration 
assays
Permeability assays were performed as previously described (Wój-
ciak-Stothard et al., 2001; McKenzie and Ridley, 2007). HUV ECs 
were plated at confluence onto fibronectin-coated transwells in 
growth medium. After 24  h they were rinsed and stimulated or 
not for 20  h with TNF (10 ng/ml in growth medium) added to the 
top chamber of the transwell. FITC-dextran (Mr 42,000; Sigma- 
Aldrich) was applied apically at 0.1 mg/ml and allowed to equilibrate 
for 60 min before a sample of the medium was removed from the 
lower chamber to measure fluorescence in the Fusion α-FS fluorim-
eter. TEER assays with an electric cell-substrate impedance sensing 
system (ECIS 1600R; Applied Biophysics; Tiruppathi et al., 1992) 
were performed as described (Fernández-Martín et al., 2012; Aranda 
et al., 2013). TEER decrease during contraction and the subsequent 
recovery was expressed as the percentage of the difference in resis-
tance detected between wells containing endothelial cells before and 
after stimulation with thrombin at the time of maximum contraction 
(1 U/ml thrombin in HUV ECs, 0.5 h stimulation) or (10 U/ml throm-
bin in HDM VEC, 1  h stimulation). For transendothelial migration 
assays, HUV ECs previously transfected with the indicated siRNAs 
were seeded at confluence on transwells with 5-µm-diameter pores 
for 48 h. T-lymphoblasts were labeled with 0.5 µm 2′,7′,-bis-(2-car-
boxyethyl)-5-(and-6)-carboxyfluorescein, acetoxymethyl ester 
(Molecular Probes) in serum-free medium for 20 min, washed with 
medium containing 10% FBS, and added to the top chamber of the 
HUV EC-containing transwells. 50 µg/ml SDF-1α was added to the 
bottom chamber as chemo attractant. After 2 h of incubation at 37°C, 
transmigrated T-lymphoblasts were harvested from the bottom cham-
ber and fluorescence was measured in a Fusion α-FS fluorimeter 
(PerkinElmer) with a 480 nm filter. P values were calculated using 
Student’s t test on a minimum of three experiments with duplicates.
Confocal and time-lapse microscopy
For confocal microscopy, cells were fixed with 4% paraformaldehyde 
for 20 min, blocked with TBS (25 mM Tris, pH 7.4, and 150 mM NaCl) 
plus 10 mM Glycine for 10 min, permeabilized for 5 min with TBS 
containing 0.2% Triton X-100 at 4°C, blocked with TBS containing 
3% BSA for 30 min and incubated at 37°C with primary antibodies 
then fluorophore-conjugated secondary antibodies and 1 µg/ml TRI TC/ 
FITC/Alexa Fluor 647–labeled phalloidin. Secondary antibodies fluo-
rophores were from Thermo Fisher Scientific and conjugated to Alexa 
Fluor 488, 555 and 647. Confocal laser scanning microscopy was per-
formed with an LSM510 (ZEI SS) coupled to an Axiovert200M micro-
scope, as previously described (Fernández-Martín et al., 2012). In brief, 
we used 40×/1.3 oil Plan-Neofluar objective for morphological studies 
and 63×/1.4 oil Plan-Apochromat and 100×/1.3 oil Plan-Neofluar ob-
jectives, for image acquisition of subcellular structures. Acquisition 
software (LSM510 4.2) was obtained from ZEI SS. Quantification of 
β-catenin and F-actin intensity were performed in ImageJ previous 
background subtraction. To quantify cell area, images of subconfluent 
cells stained for F-actin were taken. Quantification of Rac-cherry local-
ization was also performed in ImageJ. In brief, images of subconfluent 
cells transfected for Rac1-cherry and stained for F-actin were selected. 
Applying a threshold, a region containing the cell area was automat-
ically created, then made 5 to 10 pixels smaller and subtracted from 
the original region to generate a region comprising the fluorescence 
intensity at cell periphery. The main pixels intensity of Rac1-cherry 
images included in this peripheral region was quantified and compared 
with fluorescence intensity from the whole cellular area. To generate 
the mask marking empty spaces within a cell monolayer, a threshold 
to identify dark spaces was created and subsequently colored and flat-
tened to the original image.
Time-lapse microscopy was performed with an Axiovert200 
(ZEI SS) microscope, in an environmental chamber at 37°C.  A total 
of 20 mM Hepes, pH 7.4, was added to the culture medium 2 h be-
fore the experiment. Images were taken with a cooled CCD camera 
(Orca-ER C4742-95; Hamamatsu). Camera and shutter (Lambda 
Instruments) were controlled by Andor Q software. Movies were 
processed with ImageJ software. Vesicle tracking analysis was per-
formed with ImageJ plugin MTrack2 and Chemotaxis and migration 
tool software from IBI DI.
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Superresolution confocal microscopy
For stochastic optical reconstruction microscopy (STO RM), cells were 
plated in ibiTreat, 35-mm-diameter μ-dishes from IBI DI for 24  h, 
starved during 1 h, pretreated with TNF, and stimulated with throm-
bin when indicated. Immunofluorescence was performed as described 
for confocal microscopy, diluting antibodies with PBS and using the 
647N-atto fluorophore for the secondary antibodies. Before laser scan-
ning, cells were washed once with distilled water and then the buffer 
for STO RM microscopy was added (10 mM Tris, pH 8.0, 2 mM NaCl, 
2% glucose, 150 mM cysteamine, 60 mM glucose oxidase, and 2 mM 
cyclooctatetraene). Superresolution microscopy was performed on an 
Eclipse Ti-E Inverted (Nikon) with an Andor Ixon camera and NIS Ele-
ments AR software, using highly inclined illumination. Superresolution 
images were processed with the ImageJ plugin quickPALM. The anal-
ysis of particles clustering was performed using Ripley’s K-function 
(Kiskowski et al., 2009) programmed in C++. Stimulated emission de-
pletion (STED) superresolution microscopy was performed on a TCS 
SP5 II STED microscope (Leica Biosystems), with STED being used 
to detect fluorescence from the ATTO-647N fluorophore. Excitation 
was performed using a 635-nm pulsed diode laser and de-excitation 
by a MaiTai tunable fs laser at 750 nm. Superresolution images are 
presented in inverted grayscale for a clear display of features.
Immunohistochemistry
The immunohistochemical analysis of human tissues was approved by 
the hospital ethics committees of the Hospital Universitario Central de 
Asturias and the Hospital Universitario de Salamanca were performed 
as described (Reglero-Real et al., 2014). In addition to biopsies from 
the mentioned pathologies, controls corresponded to healthy donors or 
to unaffected tissue of livers or intestine resected from patients with 
carcinoma. Formalin-fixed, paraffin-embedded sections of 4-µm thick-
ness were deparaffinized in xylene and rehydrated through a decreas-
ing graded-ethanol solution series. After suppression of endogenous 
peroxidase activity (3% hydrogen peroxide, 10 min) and antigen re-
trieval (boiling in 10 mM citrate buffer, pH 6.0), immunostaining was 
performed with a mouse monoclonal antibody against human RhoB 
from Santa Cruz Biotechnology, Inc. (clone C-5). Isotype-specific 
control was performed with anti–cytokeratin-7 from Novocastra. Anti- 
proteoglycan NG2 (Santa Cruz Biotechnology, Inc.) and anti–smooth 
muscle actin (Santa Cruz Biotechnology, Inc.) were used to identify 
postcapillary venules. Staining was done by using the Envision Plus 
peroxidase mouse system (Dako). The stained protein was visualized 
using DAB solution (Dako) and lightly counterstained with Mayers- 
hematoxylin. To ascertain the specificity of the antibody immunoreac-
tivity, a negative control was performed in the absence of the primary 
antibody. In this case, no immunolabeling was detected. Immunohis-
tochemistry was also performed on a fully automated system (Bond 
III; Leica Biosystems).
Online supplemental material
Fig. S1 shows changes in RhoA, RhoB, and RhoC expression 
in HDM ECs and various cell lines. The screening of expression 
changes in response to TNF for the rest of the Rho GTPase family 
members. Fig. S2 shows the specific localization of RhoB expression 
in intestine fissures in intestines with Crohn’s disease and controls of 
the immunohistochemical analysis. Fig. S3 shows a full analysis of the 
compensatory effects of silencing individual or pairs of RhoA subfamily 
GTPases. Fig. S4 shows the effect of siRhoA, siRhoB, and siRhoC 
on F-actin levels, adherens junction morphology, and lymphocyte 
transendothelial migration in TNF-stimulated HUV ECs. Fig. S5 shows 
the lack of colocalization between endogenous RhoB and GFP-Rab4, 
GFP-Rab11, and endogenous EHD-1 in HUV ECs and the colocalization 
of endogenous RhoB with cherry-Rac1 in HDM VECs. It also shows 
the biotynilation of Rac-GFP by RhoB-BirA in pull-down assays with 
neutravidin. It also shows the effect of brefeldin A on the movement 
of Rac1-Cherry–positive vesicles. Table S1 summarizes the RhoB 
expression levels detected in various human tissues. Table S2 shows the 
primers for qPCR analyses. Videos 1 and 2 show the effect of thrombin 
on GFP-RhoB intracellular trafficking in TNF-pretreated HUV ECs. 
Videos 3 and 4 show the effect of thrombin on cherry-Rac1 intracellular 
trafficking in TNF-pretreated HUV ECs. Videos 5 and 6 show the effect 
of brefeldin A on cherry-Rac1 trafficking in TNF-pretreated, thrombin-
stimulated HUV ECs. Online supplemental material is available at 
http ://www .jcb .org /cgi /content /full /jcb .201504038 /DC1. Additional data 
are available in the JCB DataViewer at http://dx.doi.org/10.1083/jcb 
.201504038.dv.
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